KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash from Investing Activities (2016 - 2026)

Neogenomics filings provide 17 years of Cash from Investing Activities readings, the most recent being -$5.0 million for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 240.45% to -$5.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$20.9 million, a 1205.61% decrease, with the full-year FY2025 number at -$12.3 million, down 195.96% from a year prior.
  • Cash from Investing Activities hit -$5.0 million in Q1 2026 for Neogenomics, up from -$6.3 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $23.7 million in Q1 2023 to a low of -$9.3 million in Q2 2025.
  • Median Cash from Investing Activities over the past 5 years was -$277000.0 (2025), compared with a mean of $4.3 million.
  • Biggest five-year swings in Cash from Investing Activities: skyrocketed 1717.59% in 2023 and later tumbled 240.45% in 2026.
  • Neogenomics' Cash from Investing Activities stood at -$1.1 million in 2022, then skyrocketed by 1717.59% to $17.2 million in 2023, then plummeted by 131.79% to -$5.5 million in 2024, then dropped by 15.33% to -$6.3 million in 2025, then grew by 20.7% to -$5.0 million in 2026.
  • The last three reported values for Cash from Investing Activities were -$5.0 million (Q1 2026), -$6.3 million (Q4 2025), and -$277000.0 (Q3 2025) per Business Quant data.